TrialJournal of the American Heart Association2024

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.

Caroline J Coats et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.